Clinical Trials Logo
  1. Home
  2. Metastatic Uveal Melanoma
  3. NCT06121180

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma Clinical Trial

Official title:
A Phase II Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Clinical Trial Summary

The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06121180
Study type Interventional
Source H. Lee Moffitt Cancer Center and Research Institute
Contact Malik Hall
Phone 813-745-5170
Email Malik.Hall@moffitt.org
Status Recruiting
Phase Phase 2
Start date February 9, 2024
Completion date October 31, 2030
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03068624 - Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Phase 1
Recruiting NCT04728633 - Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases Phase 2
Recruiting NCT05987332 - IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Phase 2/Phase 3
Completed NCT01551459 - A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Completed NCT01585194 - Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Phase 2
Withdrawn NCT01328106 - Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma Phase 2
Recruiting NCT05075993 - Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors Phase 1
Active, not recruiting NCT04552223 - Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma Phase 2
Recruiting NCT05607095 - Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma Phase 1
Active, not recruiting NCT01587352 - Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Phase 2
Active, not recruiting NCT03025256 - Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease Phase 1
Active, not recruiting NCT03472586 - Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver Phase 2
Terminated NCT04879017 - FHD-286 in Subjects With Metastatic Uveal Melanoma Phase 1
Terminated NCT01814046 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma Phase 2
Recruiting NCT03947385 - Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Phase 1/Phase 2
Active, not recruiting NCT03865212 - Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma Phase 1
Active, not recruiting NCT05022901 - An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma Phase 3
Recruiting NCT05282901 - Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) Phase 2
Recruiting NCT05415072 - A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas Phase 1/Phase 2